Economic analysis of the 1996–1997 mass measles immunization campaigns in South Africa

Uzicanin, Amra; Zhou, Fangjun; Eggers, Rudolf; Webb, Elize; Strebel, Peter M.

doi:10.1016/j.vaccine.2004.02.042

Cited by 29 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…consumer sovereignty) and that monetary values should reflect individual willingness to exchange consumption for the outcomes of concern (e.g. [25], p. 30), lost production has also been commonly used in the CBA literature to value health [26–31]. Under these approaches, productivity loss averted due to reduction in morbidity and mortality were incorporated as indirect benefits of vaccination in terms of the wider economic effects of health as human capital (rather than its intrinsic value).…”

Section: Methodsmentioning

confidence: 99%

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Park

Jit

2018

BMC Med

View full text Add to dashboard Cite

BackgroundThere is increasing interest in estimating the broader benefits of public health interventions beyond those captured in traditional cost-utility analyses. Cost-benefit analysis (CBA) in principle offers a way to capture such benefits, but a wide variety of methods have been used to monetise benefits in CBAs.MethodsTo understand the implications of different CBA approaches for capturing and monetising benefits and their potential impact on public health decision-making, we conducted a CBA of human papillomavirus (HPV) vaccination in the United Kingdom using eight methods for monetising health and economic benefits, valuing productivity loss using either (1) the human capital or (2) the friction cost method, including the value of unpaid work in (3) human capital or (4) friction cost approaches, (5) adjusting for hard-to-fill vacancies in the labour market, (6) using the value of a statistical life, (7) monetising quality-adjusted life years and (8) including both productivity losses and monetised quality-adjusted life years. A previously described transmission dynamic model was used to project the impact of vaccination on cervical cancer outcomes. Probabilistic sensitivity analysis was conducted to capture uncertainty in epidemiologic and economic parameters.ResultsTotal benefits of vaccination varied by more than 20-fold (£0.6–12.4 billion) across the approaches. The threshold vaccine cost (maximum vaccine cost at which HPV vaccination has a benefit-to-cost ratio above one) ranged from £69 (95% CI £56–£84) to £1417 (£1291–£1541).ConclusionsApplying different approaches to monetise benefits in CBA can lead to widely varying outcomes on public health interventions such as vaccination. Use of CBA to inform priority setting in public health will require greater convergence around appropriate methodology to achieve consistency and comparability across different studies.Electronic supplementary materialThe online version of this article (10.1186/s12916-018-1130-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Park

Jit

2018

BMC Med

View full text Add to dashboard Cite

show abstract

“…SIAs are cost-effective, can improve vaccination equity within populations, and deliver other health interventions, such as vitamin A, albendazole, and insecticide-treated bed nets [50][51][52][53]. Successful SIAs need to reach all eligible children, particularly those with poor access to immunization services.…”

Section: Pan El 4 Immuni Zaɵon St Rategies -Key Research Qu Esɵon Smentioning

confidence: 99%

Research priorities for global measles and rubella control and eradication

Goodson

Chu

Rota

et al. 2012

Vaccine

View full text Add to dashboard Cite

“…Deaths can occur as a result of complications such as pneumonia, diarrhea, malnutrition, middle ear infection and encephalitis. Permanent neurological sequels can also occur, including deafness and blindness 2,6 .…”

Section: Introductionmentioning

confidence: 99%

“…Vaccination with a safe and effective vaccine which has been available since the beginning of the 1960s is the most cost-effective public health intervention for preventing this disease 4,6 . In 2001, countries covered by the World Health Organization Regional Office for Africa (WHO/ AFRO) were included in a global initiative to reduce the number of deaths from this disease 7 .…”

Section: Introductionmentioning

confidence: 99%

Impact of vaccination on the incidence of measles in Mozambique in the period 2000 to 2011

et al. 2013

View full text Add to dashboard Cite

show abstract

Economic analysis of the 1996–1997 mass measles immunization campaigns in South Africa

Cited by 29 publications

References 7 publications

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Research priorities for global measles and rubella control and eradication

Impact of vaccination on the incidence of measles in Mozambique in the period 2000 to 2011

Contact Info

Product

Resources

About